Upgrade to SI Premium - Free Trial

Grifols (GRFS)

7.80 -0.08 (1.02%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

BofA Securities Reiterates Buy Rating on Grifols SA (GRF:SM) (GRFS) September 4, 2026 6:07 AM - StreetInsider Grifols completes patient follow-up in phase 3 alpha-1 lung study August 10, 2026 7:01 AM - StreetInsider Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency August 10, 2026 7:00 AM - Globe NewsWire Form 6-K Grifols SA For: Jul 30 July 30, 2026 10:49 AM - SEC Filing Form 6-K Grifols SA For: Jul 28 July 29, 2026 6:02 AM - SEC Filing Grifols starts two Phase 3 trials to expand immunoglobulin labels July 16, 2026 8:01 AM - StreetInsider Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins July 16, 2026 8:00 AM - Globe NewsWire Form 6-K Grifols SA For: Jun 22 June 22, 2026 2:18 PM - SEC Filing Form 6-K Grifols SA For: Jun 18 June 18, 2026 4:00 PM - SEC Filing Grifols launches FESILTY fibrinogen concentrate in the US June 15, 2026 8:02 AM - StreetInsider Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. June 15, 2026 8:00 AM - Globe NewsWire Full Article List